arrow
M

Marc Sanson

Sorbonne University
H指数:85
被引数:2.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Gliomas with pleomorphic and pseudopapillary features (GPAP) are circumscribed tumors with targetable mutations, prolonged survival, and frequent tumor predisposition

具有多形性和假乳头状特征的胶质瘤(GPAP)是边界清晰的肿瘤,具有可靶向的突变、生存期延长和频繁的肿瘤易感性

2026-09-300
OAAI
Functional analysis of telomere maintenance mechanisms is more informative than immunohistochemistry for ATRX mutation interpretation in Gliomas

端粒维持机制的功能分析比免疫组化更能为胶质瘤中ATRX突变的解读提供信息。

2025-12-200
OAAI
PROGNOSTIC AND PREDICTIVE MARKERS FOR OUTCOME IN PATIENTS WITH IDHMT TUMORS TREATED IN THE EORTC CATNON TRIAL ON ADJUVANT AND/OR CONCURRENT TEMOZOLOMIDE IN ANAPLASTIC ASTROCYTOMA

IDHMT肿瘤患者在接受EORTC CATNON试验中辅助和/或同步替莫唑胺治疗的间变性星形细胞瘤中的预后和预测性生物标志物

2025-11-010
OAAI
A PHASE 2 STUDY OF PEMIGATINIB FOR PRE-TREATED GLIOBLASTOMA OR OTHER GLIOMAS WITH ACTIVATING FGFR1-3 ALTERATIONS: FINAL RESULTS FROM FIGHT-209

一项关于佩米加替尼治疗经治胶质母细胞瘤或其他携带激活性FGFR1-3变异的胶质瘤的II期研究:FIGHT-209的最终结果

2025-10-010
OAAI
DIFFUSE MIDLINE GLIOMA, H3 K27 AND BRAF/FGFR1 CO-ALTERED: DISTINCT BIOLOGY AND THERAPEUTIC OPPORTUNITIES

弥漫性中线胶质瘤,H3 K27和BRAF/FGFR1共突变:独特的生物学特征和治疗机遇

2025-10-010
OAAI
FINAL CLINICAL AND MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1P/19Q CODELETION.

EORTC随机分组III期CATNON试验的最终临床和分子分析:关于无1p/19q共缺失的间变性胶质瘤中同步和辅助替莫唑胺的应用。

2025-10-010
OAAI
DECIPHERING GLIOBLASTOMA METABOLIC SIGNATURE: MOLECULAR PROFILING AND NADH-FLIM IMAGING

解析胶质母细胞瘤代谢特征:分子谱分析与NADH-FLIM成像

2025-10-010
OAAI
DECIPHERING THE LONGITUDINAL TRAJECTORIES OF GLIOBLASTOMA ECOSYSTEMS BY INTEGRATIVE SINGLE-CELL GENOMICS

通过整合单细胞基因组学解析胶质母细胞瘤生态系统的纵向轨迹

2025-10-010
OAAI
A Specific Methylation Class Identifies BAP1-Deficient Meningiomas, Including Meningeal Tumours With Poorly Differentiated Nonrhabdoid Histology

一种特定的甲基化类别可识别BAP1缺陷型脑膜瘤,包括具有未分化非横纹样组织学的脑膜肿瘤。

2025-09-300
OAAI
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling

IDH突变型星形细胞瘤的进化轨迹识别与细胞周期相关的分子分级标志物

2025-08-190
OA
Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: Results of an international academia-driven compassionate use program

ONC201(dordaviprone)在H3K27突变型复发弥漫性中线胶质瘤患儿及成人中的真实世界数据:一项国际学界主导的同情用药计划的结果

2025-02-011
OAAI
LONGITUDINAL SINGLE-CELL ANALYSES IDENTIFY DRIVERS OF GENETIC, EPIGENOMIC, AND CELLULAR EVOLUTION IN IDH-MUTANT GLIOMA
2024-11-110
PRE
A NEW SUBTYPE OF DIFFUSE MIDLINE GLIOMA, H3 K27 AND BRAF/FGFR1 CO-ALTERED, EXHIBITS SPECIFIC BIOLOGICAL CHARACTERISTICS AND NEW THERAPEUTIC VULNERABILITIES
2024-11-110
PRE
MUTANT IDH INHIBITORS INDUCE LINEAGE DIFFERENTIATION IN IDH-MUTANT OLIGODENDROGLIOMA
2024-11-110
PRE
THE ONCOMETABOLITE D-2-HYDROXYGLUTARATE PROMOTES DNA HYPERMETHYLATION AT LINEAGE-SPECIFIC ENHANCERS CONTROLLING MICROGLIAL ACTIVATION IN IDH-MUTATED GLIOMAS
2024-10-170
PRE